These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1217 related articles for article (PubMed ID: 21376385)

  • 1. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.
    Cortes J; O'Shaughnessy J; Loesch D; Blum JL; Vahdat LT; Petrakova K; Chollet P; Manikas A; Diéras V; Delozier T; Vladimirov V; Cardoso F; Koh H; Bougnoux P; Dutcus CE; Seegobin S; Mir D; Meneses N; Wanders J; Twelves C;
    Lancet; 2011 Mar; 377(9769):914-23. PubMed ID: 21376385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, open-label, multicenter, phase 3 study to compare the efficacy and safety of eribulin to treatment of physician's choice in patients with advanced non-small cell lung cancer.
    Katakami N; Felip E; Spigel DR; Kim JH; Olivo M; Guo M; Nokihara H; Yang JC; Iannotti N; Satouchi M; Barlesi F
    Ann Oncol; 2017 Sep; 28(9):2241-2247. PubMed ID: 28911085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.
    Schöffski P; Chawla S; Maki RG; Italiano A; Gelderblom H; Choy E; Grignani G; Camargo V; Bauer S; Rha SY; Blay JY; Hohenberger P; D'Adamo D; Guo M; Chmielowski B; Le Cesne A; Demetri GD; Patel SR
    Lancet; 2016 Apr; 387(10028):1629-37. PubMed ID: 26874885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial.
    Perez EA; Awada A; O'Shaughnessy J; Rugo HS; Twelves C; Im SA; Gómez-Pardo P; Schwartzberg LS; Diéras V; Yardley DA; Potter DA; Mailliez A; Moreno-Aspitia A; Ahn JS; Zhao C; Hoch U; Tagliaferri M; Hannah AL; Cortes J
    Lancet Oncol; 2015 Nov; 16(15):1556-1568. PubMed ID: 26482278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eribulin for the treatment of advanced or metastatic breast cancer: a NICE single technology appraisal.
    Greenhalgh J; Bagust A; Boland A; Oyee J; Trevor N; Beale S; Dundar Y; Hockenhull J; Proudlove C; O'Reilly S
    Pharmacoeconomics; 2015 Feb; 33(2):137-48. PubMed ID: 25213036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy.
    Pivot X; Marmé F; Koenigsberg R; Guo M; Berrak E; Wolfer A
    Ann Oncol; 2016 Aug; 27(8):1525-31. PubMed ID: 27177860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eribulin.
    Perry CM
    Drugs; 2011 Jul; 71(10):1321-31. PubMed ID: 21770478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study.
    Yardley DA; Reeves J; Dees EC; Osborne C; Paul D; Ademuyiwa F; Soliman H; Guthrie T; Andersen J; Krekow L; Choksi J; Daniel B; Danso M; Favret A; Oommen S; Brufsky A; Bromund JL; Lin Y; Ibrahim AB; Richards PD
    Clin Breast Cancer; 2016 Dec; 16(6):471-479.e1. PubMed ID: 27569274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine.
    Cortes J; Vahdat L; Blum JL; Twelves C; Campone M; Roché H; Bachelot T; Awada A; Paridaens R; Goncalves A; Shuster DE; Wanders J; Fang F; Gurnani R; Richmond E; Cole PE; Ashworth S; Allison MA
    J Clin Oncol; 2010 Sep; 28(25):3922-8. PubMed ID: 20679609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial.
    Hayashida T; Jinno H; Mori K; Sato H; Matsui A; Sakurai T; Hattori H; Takayama S; Wada M; Takahashi M; Seki H; Seki T; Nagayama A; Matsumoto A; Kitagawa Y
    BMC Cancer; 2018 Jun; 18(1):701. PubMed ID: 29954362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results.
    Park YH; Kim TY; Im YH; Lee KS; Park IH; Sohn J; Lee SH; Im SA; Kim JH; Kim SH; Lee SJ; Koh SJ; Lee KH; Choi YJ; Cho EK; Lee S; Kang SY; Seo JH; Kim SB; Jung KH
    Cancer Res Treat; 2017 Apr; 49(2):423-429. PubMed ID: 27488876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer.
    McIntyre K; O'Shaughnessy J; Schwartzberg L; Glück S; Berrak E; Song JX; Cox D; Vahdat LT
    Breast Cancer Res Treat; 2014 Jul; 146(2):321-8. PubMed ID: 24699910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19).
    Aogi K; Watanabe K; Kitada M; Sangai T; Ohtani S; Aruga T; Kawaguchi H; Fujisawa T; Maeda S; Morimoto T; Sato N; Takao S; Morita S; Masuda N; Toi M; Ohno S
    Int J Clin Oncol; 2021 Jul; 26(7):1229-1236. PubMed ID: 33891194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and safety of eribulin mesylate: a new therapeutic option in the treatment of metastatic breast cancer.
    O'Sullivan Coyne G; Walsh J; Kelly CM
    Expert Opin Drug Saf; 2012 Jul; 11(4):643-50. PubMed ID: 22694309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trial.
    Aftimos P; Polastro L; Ameye L; Jungels C; Vakili J; Paesmans M; van den Eerenbeemt J; Buttice A; Gombos A; de Valeriola D; Gil T; Piccart-Gebhart M; Awada A
    Eur J Cancer; 2016 Jun; 60():117-24. PubMed ID: 27107326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial.
    Yuan P; Hu X; Sun T; Li W; Zhang Q; Cui S; Cheng Y; Ouyang Q; Wang X; Chen Z; Hiraiwa M; Saito K; Funasaka S; Xu B
    Eur J Cancer; 2019 May; 112():57-65. PubMed ID: 30928806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.
    Pernas S; Martin M; Kaufman PA; Gil-Martin M; Gomez Pardo P; Lopez-Tarruella S; Manso L; Ciruelos E; Perez-Fidalgo JA; Hernando C; Ademuyiwa FO; Weilbaecher K; Mayer I; Pluard TJ; Martinez Garcia M; Vahdat L; Perez-Garcia J; Wach A; Barker D; Fung S; Romagnoli B; Cortes J
    Lancet Oncol; 2018 Jun; 19(6):812-824. PubMed ID: 29706375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eribulin: Heavily pretreated breast cancer: uncertain advantages, excessive adverse effects.
    Prescrire Int; 2012 Feb; 21(124):37-8. PubMed ID: 22413716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study.
    Ortega V; Antón A; Garau I; Afonso N; Calvo L; Fernández Y; Martínez-García M; Blanco E; Zamora P; García M; Illarramendi JJ; Rodríguez Sánchez CA; Sampayo M; Aguirre E; Pérez-García JM; Cortés J; Llombart-Cussac A
    Clin Breast Cancer; 2019 Apr; 19(2):105-112. PubMed ID: 30679100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
    Vahdat LT; Pruitt B; Fabian CJ; Rivera RR; Smith DA; Tan-Chiu E; Wright J; Tan AR; Dacosta NA; Chuang E; Smith J; O'Shaughnessy J; Shuster DE; Meneses NL; Chandrawansa K; Fang F; Cole PE; Ashworth S; Blum JL
    J Clin Oncol; 2009 Jun; 27(18):2954-61. PubMed ID: 19349550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 61.